文献速递脑血管病

DNase1 rs1053874多态性通过NET调控与缺血性卒中早期神经恢复及长期生存相关

DNase1 RS1053874 Polymorphism is Associated with Early Neurological Recovery through NET Modulation and with Long-Term Survival in Ischemic Stroke: A Prospective Cohort Study.
PubMed 文献 · Ann Neurol · 2026-01-13

这项前瞻性队列研究纳入492例急性缺血性卒中患者,检测DNase1 rs1053874基因型并分析NET生物标志物、梗死体积、取栓次数和生存。AA基因型携带者(7.9%)入院时DNase1活性更高、循环NET标志物更低,取栓次数更少、早期神经恢复更好且梗死体积更小;AA基因型与血脂异常均独立关联长期生存改善。

要点

  • AA基因型携带者入院时DNase1活性更高、循环NET标志物更低。
  • AA基因型携带者取栓次数更少、早期神经恢复更好、梗死体积更小。
  • AA基因型与血脂异常均独立关联长期生存改善。

核心结论

  • DNase1 rs1053874多态性影响NET相关炎症,与缺血性卒中患者更好的血管风险特征、取栓效率和长期结局相关。

研究设计与样本

  • 前瞻性观察性队列研究纳入492例急性缺血性卒中患者,采用Sanger测序对rs1053874分型并按AA对GG+GA显性模型分析。

主要发现

  • AA基因型携带者占7.9%,其既往血管事件负担显著低于GG+GA携带者。
  • 入院时AA携带者DNase1活性更高,循环NET标志物(弹性蛋白酶、MPO、dsDNA)水平更低,中性粒细胞和单核细胞计数更低。
  • 尽管初始卒中严重程度相似,AA携带者所需取栓次数更少,早期神经恢复显著更好且梗死体积更小。
  • 校正模型中AA基因型和血脂异常均独立关联长期生存改善,分层分析显示无血脂异常的AA携带者生存获益最明显,未观察到显著交互作用。

临床怎么用

  • DNase1 rs1053874基因型可能作为缺血性卒中预后评估的候选标志物。
  • DNase1及NET通路可能成为个性化卒中治疗的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immunothrombosis contributes to ischemic stroke pathophysiology through neutrophil extracellular trap (NET) formation, which promotes thrombus stabilization and microvascular dysfunction. DNase1 is the principal endonuclease responsible for NET degradation. The rs1053874 polymorphism in DNase1 gene influences enzymatic activity and protein stability in vitro, but its clinical relevance in ischemic stroke remains unexplored. We investigated whether this variant modulates systemic NET burden and impacts stroke-related outcomes. METHODS: We conducted a prospective observational cohort study including 492 patients with acute ischemic stroke. Genotyping of rs1053874 was performed via Sanger sequencing and categorized into AA versus GG + GA genotypes (dominant model). Clinical variables, NET biomarkers (elastase, myeloperoxidase [MPO], and dsDNA), DNAse1 activity, infarct volume, thrombectomy metrics, and survival were assessed. Multivariable regression and Cox proportional hazards models were used to explore associations between genotype and outcomes. RESULTS: AA genotype carriers (7.9%) had a significantly lower burden of prior vascular events compared to GG + GA carriers. At admission, they exhibited higher DNAse1 activity, reduced levels of circulating NET markers (elastase, MPO, and dsDNA), and lower neutrophil and monocyte counts. Despite similar initial stroke severity, AA carriers required fewer thrombectomy passes and had significantly better early neurological recovery and smaller infarcts. In adjusted models, both the AA genotype and dyslipidemia were independently associated with improved long-term survival. However, stratified analyses revealed the most robust survival benefit among AA carriers without dyslipidemia. No significant interaction was observed. INTERPRETATION: DNase1 rs1053874 polymorphism influences NET-related inflammation and is associated with improved vascular profile, procedural efficiency, and long-term outcomes in ischemic stroke. These findings support the potential of DNase1 as a therapeutic and prognostic target in personalized stroke care. ANN NEUROL 2026;99:1210-1223.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Díaz-Benito B, Calleja P, Alzamora L, et al. DNase1 RS1053874 Polymorphism is Associated with Early Neurological Recovery through NET Modulation and with Long-Term Survival in Ischemic Stroke: A Prospective Cohort Study. Ann Neurol. 2026. PMID: 41527943. doi:10.1002/ana.78156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。